Possible captopril-induced toxic epidermal necrolysis.
OBJECTIVE
To report a case of toxic epidermal necrolysis (TEN) possibly induced by captopril.


METHODS
An 11-week-old boy was referred to our hospital for tetrology of fallot surgical repair, performed on admission day 2. On day 3, the patient developed third-degree heart block, necessitating pacemaker connection and oral theophylline 3 mg/kg 3 times daily. Captopril 1 mg orally twice daily, intravenous furosemide 7 mg every 12 hours, and oral aldactone 7 mg twice daily were started. On day 5, the patient developed scaling erythematous skin lesions. On day 7, his temperature spiked to 37.8 degrees C, and pus discharge from the pacing wire site was noticed. Intravenous vancomycin 80 mg 3 times daily and intravenous ceftazidime 200 mg 3 times daily were initiated. On the same day, captopril was discontinued because we suspected that it had induced the skin reaction. On day 15, the infant's skin problem progressed. The dermatologist diagnosed partial TEN. On that day, theophylline and furosemide were also discontinued. On day 16, the patient still had some blisters, but the skin started to show signs of healing, until complete healing occurred on day 22. The infant was discharged on oral medications: furosemide 7 mg twice daily, aldactone 7 mg twice daily, and enalapril 0.1 mg twice daily. Three weeks later, he was followed up. No recurrences were observed.


CONCLUSIONS
This case suggests captopril induces TEN when combined with other sulfonamide medications. An objective causality assessment revealed that the adverse drug event was possible. Although it is a rare complication, healthcare providers should be familiar with its potential to occur and take appropriate treatment and prevention measures.
Alkurtass
Delal A
DA
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Al-Jazairi
Abdulrazaq S
AS
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D002216:Captopril / Q000009:adverse effects*; D003879:Dermatologic Agents / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D012837:Silver Sulfadiazine / Q000627:therapeutic use; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy / Q000209:etiology*; D015034:Zinc Oxide / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D003879:Dermatologic Agents; D002216:Captopril; D015034:Zinc Oxide; D012837:Silver Sulfadiazine